Industrial disease meaning

In this issue: EU fundamentals Commercial Competition and state aid Banking and finance Corporate Data protection and cybersecurity Financial services Energy Environment Insurance and reinsurance IP Life sciences Regulatory TMT International trade Daily and weekly news alerts New and updated content Trackers and horizon scanners EU fundamentals The Commission has launched a four-week call for evidence to shape technical guidance on applying the ‘do no significant harm’ principle within the 2028–34 multiannual financial framework. Required by Article 5 of the proposed Regulation establishing a budget expenditure tracking and performance framework, the guidance will be applied where feasible and appropriate. The evidence window closes on 1 April 2026, with adoption scheduled for Q4 2026. See: LNB News 04/03/2026 56. Commercial: The Council of the EU has agreed conclusions to steer delivery of the 2030 Consumer Agenda, urging enhanced consumer protection—particularly online—greater encouragement of sustainable consumption, stronger...

In this issue: Pharmaceuticals-regulatory framework Medical devices Research and development Daily and weekly news alerts New and updated content Trackers and horizon scanning Useful information Pharmaceuticals-regulatory framework MHRA launches consultation on draft rare disease therapies framework The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on a draft Rare Disease Therapies Regulatory Framework. The plans would establish an Investigational Marketing Authorisation to permit controlled early access to rare disease treatments while further clinical and real‑world data are collected. The consultation closes on 30 July 2026. See: LNB News 21/05/2026 31. Commission publishes analysis proposing Biotech Act measures The European Commission has issued a staff working document outlining the analysis supporting its proposed Biotech Act, first unveiled in December 2025. Aimed at reinforcing Europe’s biotechnology and biomanufacturing base, with a strong emphasis on health, the Act intends to accelerate the development, production and market uptake of biotechnology‑based innovations across the EU. The...

Abbott and others v Ministry of Defence [2022] EWHC 1807 (QB) What are the practical implications of this case? Practitioners acting for a cohort of claimants, each with distinct claims and fact patterns, should think carefully before placing the whole cohort on a single claim form. They must assess whether all claims can be conveniently resolved within one set of proceedings, considering both the size of the cohort and the extent of overlap between cases. A shared defendant and a handful of common issues will not, by themselves, justify a bulk claim form. Industrial disease actions featuring differing exposure periods and circumstances are particularly unlikely to be suitable for collective disposal in one action. Where any uncertainty exists, separate claim forms must be filed and individual court fees paid. This demands robust administrative processes to avoid missing limitation deadlines and brings significant cost implications. Early, structured planning is therefore essential. Importantly, a formal GLO does not provide a route to avoid issuing individual claim forms or paying...

ARCHIVED: This Practice Note has been archived and is not maintained. It distils key legal developments relevant to personal injury and clinical negligence practitioners as at 30 October 2023. For matters predating this horizon scanner, see PI and Clinical Negligence horizon scanning—overview. Key PI & Clinical negligence developments Minutes from Official Injury Claim Advisory Group’s 19 July 2023 meeting published The Ministry of Justice (MoJ) has released the minutes of the Official Injury Claim (OIC) Advisory Group meeting held on 19 July 2023. Attendees were: Chair and Secretariat from the MoJ OIC service operators from the Motor Insurers’ Bureau (MIB) Association of Personal Injury Lawyers (APIL) Motor Accident Solicitors Society (MASS) Forum of Insurance Lawyers (FOIL) Association of British Insurers (ABI) HM Courts and Tribunals Service (HMCTS) During the meeting, the MIB summarised the latest OIC data, described work on filtering dormant claims, and delivered updates based on user and member feedback. Agreed...

ARCHIVED: This Practice Note has been archived and is no longer maintained. It provides a concise overview of significant legal developments relevant to personal injury and clinical negligence practitioners as at 14 December 2022. For the latest horizon scanner, refer to PI and Clinical Negligence horizon scanning—overview. Key PI & clinical negligence developments How does the ASHE data released in October 2022 impact personal injury claims? Jodie McAuley, senior associate at Clyde & Co, and Kate Mikolajewski, Solicitor and Catastrophic and Large Loss Injury manager at Clyde & Co, explore the updates from the Office for National Statistics (ONS), including practical points to bear in mind when managing periodical payment orders. See News Analysis: How does the ASHE data released in October 2022 impact personal injury claims? Law bodies call for urgent changes to court system A solicitors’ representative body cautioned on 17 November 2022 that cuts to justice spending following the UK government’s latest...

Alternative routes for occupational disease compensation Understandably, claimant practitioners will first direct their efforts towards a common law action in the civil courts for occupational disease. There are, however, occasions when that conventional route is unavailable to the client. This may stem from how the illness was contracted and, frequently, the absence of an identifiable tortfeasor (or at least one with insurance). In such cases, a range of statutory and administrative compensation schemes may offer an alternative avenue of redress. For civil claims for mesothelioma sufferers, see Practice Note: Mesothelioma claims—procedure. For each scheme identified, this Practice Note sets out the particular circumstances in which turning to the scheme may be appropriate... The Pneumoconiosis etc (Workers’ Compensation) Act 1979 (P(WC)A 1979) Definition Pneumoconiosis describes a group of conditions arising from the inhalation and retention of dust within the lungs. Applying Apply by completing the relevant section of the ‘Mesothelioma and other lung diseases (PWC1)’ form and returning it to: Barnsley Industrial...